Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
This can be because of high stomach acid or even age
A Phase 2 trial (NCT01311518) was designed to test RGN-352 in ~75 heart attack patients, but was placed on FDA clinical hold in 2011 due to manufacturing (GMP) compliance issues at the contract site not safety concerns with the drug itself
QD community oral or SC MOTS-c Daily SC, often 5 days on / 2 off AOD-9604 Daily SC Attribute Max studied dose SLU-PP-332 50 mg/kg BID (mouse, 28 days) MOTS-c 5-15 mg/kg (mouse) AOD-9604 1-5 mg/day in human Phase 2 Attribute Peak efficacy signal SLU-PP-332 ~25-30% fat-mass reduction in DIO mice over 28 days MOTS-c Improved insulin sensitivity in aged mice AOD-9604 Modest fat-loss signal in human Phase 2
It regulates blood sugar and boosts metabolism
US$ 28.66
US$ 22.12
US$ 28.75
US$ 28.20
US$ 27.58
US$ 22.44
US$ 28.19
US$ 25.04
US$ 24.22
US$ 24.81
US$ 22.63
US$ 24.70
US$ 26.69
